Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous immunoglobulin versus convalescent plasma in severe or critical COVID-19
IRCT20200413047056N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of immune globulin and convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Lung involvement on imaging, Oxygen saturation and 7 more. Started Apr 2020; status: completed.
02
Drugs
immune globulinconvalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200413047056N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200413047056N1.